• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部癌症调强放疗中腮腺体积收缩的两变量线性模型。

A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer.

机构信息

Medical Physics Department, San Raffaele Scientific Institute, Milano, Italy.

出版信息

Radiother Oncol. 2010 Feb;94(2):206-12. doi: 10.1016/j.radonc.2009.12.014. Epub 2010 Feb 1.

DOI:10.1016/j.radonc.2009.12.014
PMID:20117852
Abstract

PURPOSE

To assess anatomical, clinical and dosimetric pre-treatment parameters, possibly predictors of parotid shrinkage during radiotherapy of head and neck cancer (HNC).

MATERIALS

Data of 174 parotids from four institutions were analysed; patients were treated with IMRT, with radical and adjuvant intent. Parotid shrinkage was evaluated by the volumetric difference (DeltaV) between parotid volumes at the end and those at the start of the therapy, as assessed by CT images (MVCT for 40 patients, KVCT for 47 patients). Correlation between DeltaVcc/% and a number of dosimetric, clinical and geometrical parameters was assessed. Univariate as well as stepwise logistic multivariate (MVA) analyses were performed by considering as an end-point a DeltaVcc/% larger than the median value. Linear models of DeltaV (continuous variable) based on the most predictive variables found at the MVA were developed.

RESULTS

Median DeltaVcc/% were 6.95 cc and 26%, respectively. The most predictive independent variables of DeltaVcc at MVA were the initial parotid volume (IPV, OR: 1.100; p=0.0002) and Dmean (OR: 1.059; p=0.038). The main independent predictors of DeltaV% at MVA were age (OR: 0.968; p=0.041) and V40 (OR: 1.0338; p=0.013). DeltaVcc and DeltaV% may be well described by the equations: DeltaVcc=-2.44+0.076 Dmean (Gy)+0.279 IPV (cc) and DeltaV%=34.23+0.192 V40 (%)-0.2203 age (year). The predictive power of the DeltaVcc model is higher than that of the DeltaV% model.

CONCLUSIONS

IPV/age and Dmean/V40 are the major dosimetric and clinical/anatomic predictors of DeltaVcc and DeltaV%. DeltaVcc and DeltaV% may be well described by bi-linear models including the above-mentioned variables.

摘要

目的

评估头颈部癌症(HNC)放疗中腮腺退缩的解剖学、临床和剂量学的预处理参数,这些参数可能是预测因素。

材料

对四个机构的 174 个腮腺的数据进行了分析;患者接受了调强放疗(IMRT),包括根治性和辅助性治疗。通过 CT 图像(40 例患者为 MVCT,47 例患者为 KVCT)评估治疗前后腮腺体积的体积差(DeltaV)来评估腮腺退缩。评估了 DeltaVcc/%与多种剂量学、临床和几何参数之间的相关性。通过考虑终点为 DeltaVcc/%大于中位数的情况,进行了单变量和逐步逻辑多元分析(MVA)。根据 MVA 中发现的最具预测性的变量,建立了基于 DeltaV(连续变量)的线性模型。

结果

DeltaVcc/%的中位数分别为 6.95 cc 和 26%。MVA 中 DeltaVcc 的最具预测性的独立变量是初始腮腺体积(IPV,OR:1.100;p=0.0002)和 Dmean(OR:1.059;p=0.038)。MVA 中 DeltaV%的主要独立预测因子是年龄(OR:0.968;p=0.041)和 V40(OR:1.0338;p=0.013)。DeltaVcc 和 DeltaV%可以通过以下方程很好地描述:DeltaVcc=-2.44+0.076 Dmean(Gy)+0.279 IPV(cc)和 DeltaV%=34.23+0.192 V40(%)-0.2203 age(年)。DeltaVcc 模型的预测能力高于 DeltaV%模型。

结论

IPV/年龄和 Dmean/V40 是 DeltaVcc 和 DeltaV%的主要剂量学和临床/解剖学预测因子。DeltaVcc 和 DeltaV%可以通过包含上述变量的双线性模型很好地描述。

相似文献

1
A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer.头颈部癌症调强放疗中腮腺体积收缩的两变量线性模型。
Radiother Oncol. 2010 Feb;94(2):206-12. doi: 10.1016/j.radonc.2009.12.014. Epub 2010 Feb 1.
2
Density variation of parotid glands during IMRT for head-neck cancer: correlation with treatment and anatomical parameters.头颈部癌症调强放疗中腮腺密度的变化:与治疗和解剖参数的相关性。
Radiother Oncol. 2012 Aug;104(2):224-9. doi: 10.1016/j.radonc.2012.06.003. Epub 2012 Jul 16.
3
Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.调强放射治疗(IMRT)治疗的头颈癌患者中,腮腺初始体积在口干症中的重要性。
Jpn J Clin Oncol. 2005 Jul;35(7):375-9. doi: 10.1093/jjco/hyi108. Epub 2005 Jun 23.
4
Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.头颈部癌逆向计划调强放射治疗(IMRT)后口腔健康相关生活质量和唾液流速的保留情况
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):663-73. doi: 10.1016/S0360-3016(03)01571-2.
5
The Shape of Parotid DVH Predicts the Entity of Gland Deformation During IMRT for Head and Neck Cancers.腮腺剂量体积直方图的形状可预测头颈部癌调强放疗期间腺体变形情况。
Technol Cancer Res Treat. 2015 Dec;14(6):683-91. doi: 10.7785/tcrt.2012.500440. Epub 2014 Nov 26.
6
Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study.头颈部癌患者术后放疗时腮腺和颌下腺的放射性体积变化:一项纵向研究
Laryngoscope. 2009 Oct;119(10):1966-74. doi: 10.1002/lary.20601.
7
Geometric factors influencing dosimetric sparing of the parotid glands using IMRT.使用调强放射治疗(IMRT)时影响腮腺剂量学保护的几何因素。
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):296-304. doi: 10.1016/j.ijrobp.2006.05.028.
8
Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines.头颈部调强放射治疗的靶区体积定义:PARSPORT试验指南的临床前评估
Clin Oncol (R Coll Radiol). 2007 Oct;19(8):604-13. doi: 10.1016/j.clon.2007.07.001. Epub 2007 Aug 13.
9
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.头颈部癌放疗患者唾液功能的剂量-体积建模
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1055-69. doi: 10.1016/j.ijrobp.2004.12.076.
10
Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.头颈部癌保留腮腺的适形放疗后的复发情况。
Radiother Oncol. 2004 Aug;72(2):119-27. doi: 10.1016/j.radonc.2004.03.014.

引用本文的文献

1
Advances in radiotherapy for mouth neoplasms: emerging technologies and future perspectives.口腔肿瘤放射治疗的进展:新兴技术与未来展望。
Discov Oncol. 2025 Jul 23;16(1):1392. doi: 10.1007/s12672-025-03249-w.
2
Biomechanics-driven dose stress metrics for radiation-induced acute xerostomia prediction among head and neck radiation therapy.头颈部放射治疗中用于预测放射性急性口干症的生物力学驱动剂量应激指标
Phys Eng Sci Med. 2025 May 13. doi: 10.1007/s13246-025-01558-6.
3
Parotid Gland Stem Cell Preservation during Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Dosimetric Analysis and Feasibility.
鼻咽癌调强放射治疗期间腮腺干细胞的保护:剂量学分析及可行性
J Oncol. 2022 Jul 12;2022:4922409. doi: 10.1155/2022/4922409. eCollection 2022.
4
MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands.磁共振引导的头颈部癌自适应放疗:主要唾液腺迁移和解剖学变化的前瞻性评估
Cancers (Basel). 2021 Oct 28;13(21):5404. doi: 10.3390/cancers13215404.
5
Investigation of Radiation-Induced Toxicity in Head and Neck Cancer Patients through Radiomics and Machine Learning: A Systematic Review.通过放射组学和机器学习对头颈部癌患者辐射诱导毒性的研究:一项系统综述
J Oncol. 2021 Jun 9;2021:5566508. doi: 10.1155/2021/5566508. eCollection 2021.
6
Correlation between 3D scanner image and MRI for tracking volume changes in head and neck cancer patients.三维扫描仪图像与 MRI 用于跟踪头颈部癌症患者的体积变化的相关性。
J Appl Clin Med Phys. 2021 Mar;22(3):86-93. doi: 10.1002/acm2.13181. Epub 2021 Feb 1.
7
Accurate estimation of daily delivered radiotherapy dose with an external treatment planning system.使用外部治疗计划系统准确估算每日放疗剂量。
Phys Imaging Radiat Oncol. 2020 May 29;14:39-42. doi: 10.1016/j.phro.2020.05.005. eCollection 2020 Apr.
8
Imaging for Response Assessment in Radiation Oncology: Current and Emerging Techniques.影像学在放射肿瘤学中的应用:当前和新兴技术。
Hematol Oncol Clin North Am. 2020 Feb;34(1):293-306. doi: 10.1016/j.hoc.2019.09.010. Epub 2019 Oct 31.
9
Delta-radiomics features during radiotherapy improve the prediction of late xerostomia.放疗过程中的 Delta 放射组学特征可改善口干症晚期的预测。
Sci Rep. 2019 Aug 28;9(1):12483. doi: 10.1038/s41598-019-48184-3.
10
Impact of adaptive intensity-modulated radiotherapy on the neutrophil-to-lymphocyte ratio in patients with nasopharyngeal carcinoma.适应性调强放疗对鼻咽癌患者中性粒细胞与淋巴细胞比值的影响。
Radiat Oncol. 2019 Aug 22;14(1):151. doi: 10.1186/s13014-019-1350-9.